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Abstract
Background: Adult-onset primary lower limb dystonia (AOPLLD) has been reported as an early sign of Parkinson’s disease (PD) or Parkinson-plus syndrome in
case series. No prior systematic analysis has assessed clinical clues predicting later development of PD or Parkinson-plus syndrome.
Methods: We identified patients with AOPLLD from medical records. We excluded patients who had not been diagnosed by a neurologist, and who had a pre-
existing diagnosis of PD, psychogenic, or secondary dystonia. Records were subdivided into those who later developed PD or Parkinson-plus disorders and those
who did not. The following clinical characteristics were compared between the two groups: dystonia onset age, type of dystonia, levodopa response, anticholinergic
response, and family history of Parkinsonism or tremor.
Results: Twenty-two AOPLLD patients were identified: 77% female; the median dystonia onset age was 53 years. Eight (37%) developed Parkinson’s disease; 2
(9%) developed corticobasal syndrome. Twelve patients (54%) did not develop Parkinsonism after a median follow-up period of 1.5 years. There was a significant
difference in leg dystonia levodopa response between the two groups (p50.02).
Conclusion: In patients with AOPLLD, leg dystonia with levodopa response is associated with the future development of PD.
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Introduction
Childhood-onset lower limb dystonia characterizes primary dystonia
such as DYT1 or DYT6, whereas adult-onset primary lower limb
dystonia (AOPLLD) can be an initial presentation of Parkinson’s
disease (PD),1 corticobasal syndrome, psychogenic dystonia, or stiff-
limb syndrome.2 AOPLLD that does not progress to a secondary cause
is being increasingly recognized.3,4 There has been no systematic
analysis for the clinical indicators towards a later development of PD
or Parkinson-plus syndrome.
Methods
We performed a retrospective medical record review of adult
patients with an initial diagnosis of primary lower limb dystonia
using the Medical Records Linkage System, from 1998 to 2011.
Patients were excluded if not diagnosed by a neurologist or if they
had a pre-existing diagnosis of PD, Parkinson-plus syndrome, or
psychogenic or secondary dystonia. The diagnosis of parkinsonism
was based on the presence of bradykinesia with at least two of the
three following signs: rest tremor, rigidity, or impaired postural
reflexes. Records were subdivided into those who later developed
PD or Parkinson-plus disorders and those who did not. Clinical
characteristics such as age of onset, type of dystonia, response to
levodopa, anticholinergics, and family history of parkinsonism or
tremor were compared between the two groups. The leg dystonia
response to levodopa or anticholinergic medication was defined by
serial clinical examinations by a neurologist. Group comparisons
were made using the x2 test for binary data and the Mann–Witney
U-test for continuous variables, using JMP software. Statistical
significance was set at p,0.05.
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Results
Out of 174 patients, 152 were excluded: 37 patients with pre-
existing PD, 13 patients with lower extremity trauma preceding
dystonia, five patients with psychogenic dystonia, 30 patients with
secondary dystonia, 10 patients with childhood-onset lower limb
dystonia, 49 patients did not have a final diagnosis of dystonia (for
example, spasticity, radiculopathy, complex regional pain syndrome,
or stiff-man syndrome) when they saw a neurologist; six patients did
not follow-up and two patients were excluded because the follow-up
period was less than 0.5 years. Twenty-two patients were identified
with AOPLLD with a median follow-up of 1.5 years (range 0.5–
22 years) (Tables 1 and 2); 21 out of 22 patients tried levodopa
whereas 17 out of 22 patients did not try anticholinergic medication.
Only three patients tried a dopamine agonist and all had improvement
in dystonia. Baclofen, botulinum toxin injection and clonazepam were
trialed, with various successes, in a small number of subjects (Table 3).
There were no statistically significant differences in the other clinical
characteristics between the two groups. These characteristics were
positive family history for parkinsonism or tremor, age of dystonia
onset, sex, or type of dystonia.
Group 1: later developed PD or Parkinson-plus syndrome (Cases
13–22).
Ten patients developed PD or corticobasal syndrome after a median
period of 1 year (0.5–3 years) after onset of lower limb dystonia. Eight
patients had PD and two patients developed corticobasal syndrome.
Group 1 had significantly greater leg dystonia levodopa response than
group 2 (p50.02). Only eight out of nine patients who developed PD
tried levodopa as one patient had declined a levodopa trial. Seven of
these eight patients had levodopa-responsive leg dystonia, and the non-
responder was unable to tolerate more than 600 mg daily because of
nausea. The two patients who later developed corticobasal syndrome
had lower limb dystonia that did not respond to levodopa. Table 2 has
a summary of the clinical characteristics.
Group 2: adult-onset primary lower limb dystonia that did not
develop parkinsonism after follow-up (Cases 1–12).
Twelve patients did not develop parkinsonism or other diagnosis
after a median follow-up of 1.5 years (0.5–3 years). Ten had leg
dystonia not responsive to levodopa at the mean dose of 600 mg daily.
Two out of four patients who tried anticholinergic medication had a
beneficial response.
Discussion
The genetic forms of PD, for example, parkin, DJ-1,5 PINK16 gene
mutation have been associated with an initial presentation of leg
dystonia. Patients with parkin mutation can present with foot dystonia
with response to levodopa.7 Foot dystonia more commonly occurs at
rest, but exercise-induced foot dystonia has been reported. In the
genetic causes of PD, the age of onset is 32–43 years, earlier than the
age of onset of our subjects.
Glut-1 gene mutation presents mainly in childhood with paroxysmal
exercise-induced dystonia. The oldest reported age of onset for Glut-1
gene mutation is 30 years. In our study, three subjects were long-
distance runners who had leg dystonia during running. They did not
develop PD after 2 years of follow-up. Although idiopathic PD cannot
Table 1. Comparison of the Clinical Characteristics between the Two Groups
Developed Parkinsonism
(n510)
Did Not Develop Parkinsonism
(n512)
p Value
Leg dystonia with levodopa response 7 (70%) 2 (16%) 0.02
Family history of Parkinson’s disease or
tremor
5 (50%) 3 (25%) 0.22
Type of dystonia (action/rest) 7 (70%)/3 (30%) 7 (58%)/5 (42%) 0.57
Gender (F/M) 9 (90%)/1 (10%) 8 (66%)/4 (33%) 0.19
Age of onset (years; range) 49 (22–75) 53 (31–71) 0.59
Table 2. Summary of the Clinical Characteristics between the Two Groups
Developed Parkinsonism
(n510)
Did Not Develop Parkinsonism
(n512)
Median follow-up period (years; range) 2 (0.5–22) 1 (0.5–9)
Median time from leg dystonia onset to Parkinsonism (years; range) 1 (0.5–3) NA
Median effective levodopa dose (mg; range) 600 (350–800) NA
Developed corticobasal syndrome 2 0
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1 No No 59 Action F No (75 mg) Not tried No 9
2 No No 55 Rest M No Not tried No 3
3 No No 64 Action F No No No 5 Responded to baclofen
but not to clonazepam
4 No No 71 Rest F No
(1500 mg)
No No 1 Responded to
botulinum toxin A
injection
5 No No 31 Action F No (750 mg) Yes (12 mg) No 0.5




7 No No 63 Rest M No Not tried Yes 1
8 No No 43 Action M No (300 mg) Not tried No 0.5 Long distance runner
9 No No 40 Action F Yes (300 mg) Not tried No 2 Long distance runner
10 No No 36 Action F No (600 mg) Not tried No 2 Long distance runner
11 No No 61 Action M No (900 mg) Not tried Yes 1
12 No No 55 Rest F Yes (750 mg) Not tried No 1 Responded to ropinirole
13 No Yes (8 years) 37 Action F No (750 mg) Yes No 8


































































































No 73 Rest F Yes (600 mg) Not tried Yes 2 Responded to
clonazepam, no benefit
baclofen 30 mg
18 Yes (1 year
later)
No 41 Action F Not tried Not tried No 1
19 Yes (2 years
later)
No 75 Action F Yes (300 mg) Not tried No 8
20 Yes
(2 years)
No 43 Action F Yes (600 mg) Not tried Yes 1
21 Yes
(2 years)





No 43 Action F Yes (750 mg) Not tried Yes 22 Responded to
pramipexole 3 mg


























































be excluded, our three patients probably had adult-onset primary
lower limb dystonia or runner’s dystonia8 rather than Glut-1 gene
mutation or genetic forms of PD, given the older age at onset and the
lack of signs to suggest secondary dystonia.
We did not screen the patients with levodopa-responsive lower limb
dystonia for dopa-responsive dystonia (DRD), which presents with
dystonia in childhood. In DRD, leg dystonia presenting in adulthood
has not been reported and should not be considered as a differential
diagnosis of adult-onset leg dystonia.
We found approximately half the patients with an initial diagnosis of
primary lower limb dystonia later developed parkinsonism. Most of
these patients developed parkinsonism 2 years after the onset of leg
dystonia. In our study, we found leg dystonia responsive to levodopa is
associated with the later development of PD. However, an absence of
levodopa response does not exclude the future possibility of developing
PD.
Alternatively, the 123I-ioflupane SPECT (single-photon emission
computed tomography) scan can be useful to differentiate between
primary lower limb dystonia and secondary dystonia from parkinson-
ism. A case report found the 123I-ioflupane SPECT scan made an early
diagnosis of PD in a patient with exercise-induced dystonia.9 We argue
that the 123I-ioflupane SPECT scan is not as affordable or accessible as
levodopa; in addition it does not differentiate between idiopathic PD
and atypical parkinsonian syndromes,10 which do not respond to
levodopa.
Our study has two limitations: it is retrospective in nature and has a
short median follow-up period of 1.5 years. The development of PD
has been reported 14 years after an initial presentation with leg
dystonia. Therefore, we may have missed patients who developed PD
after 1.5 years. A prospective study with long-term follow-up would be
useful although difficult to conduct in this rare patient population.
In summary, for patients with adult-onset primary lower limb
dystonia, a response to levodopa is associated with the future
development of PD. In contrast, an absence of levodopa response
does not exclude the development of PD, corticobasal syndrome, or
primary lower limb dystonia.
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